Form 4: Svetlana Lucas Acquires ATYR Pharma Stock Options

Svetlana Lucas, a Director at ATYR Pharma Inc., acquired 50,000 stock options with an exercise price of $0.95.

Summary

• Svetlana Lucas, a Director of ATYR Pharma Inc., was granted 50,000 stock options on May 11, 2026.
• These options have an exercise price of $0.95 per share.
• The options are set to vest in full on May 11, 2027, or at the company's 2027 Annual Meeting of Stockholders, whichever comes first, provided Ms. Lucas continues to serve on the Board of Directors.
• The underlying securities are 50,000 shares of Common Stock.
• This transaction is part of the Issuer's non-employee director compensation policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation grant to a director rather than a significant financial event or strategic shift for the company.

Positives

• Director Svetlana Lucas has been granted stock options, indicating continued confidence and alignment with the company's performance.
• The grant of 50,000 options provides a potential upside for the director tied to the company's stock price appreciation.

Risks

• The value of the stock options is contingent on the future performance of ATYR Pharma's stock price.
• Continued service on the Board of Directors is a condition for vesting, meaning Ms. Lucas could forfeit the options if she ceases to serve.

Future Outlook

The stock options granted to Svetlana Lucas vest on May 11, 2027, or at the company's 2027 Annual Meeting of Stockholders, subject to her continued service. The exercise price is $0.95.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biopharmaceutical industry to incentivize leadership and align their interests with shareholders, particularly in companies focused on development and growth.

Related Party Transactions

• The stock option grant to Director Svetlana Lucas is part of the Issuer's non-employee director compensation policy.

Stakeholder Impact

• Shareholders: The grant aligns director incentives with potential stock price appreciation.
• Employees: Standard compensation practice for directors, indirectly reflecting company operations.
• Management: Reinforces standard compensation structures for board members.

Next Steps

• Svetlana Lucas will continue to serve on the Board of Directors.
• The stock options will vest on May 11, 2027, or at the 2027 Annual Meeting of Stockholders, contingent on continued service.

Key Dates

Keywords

Form 4, Stock Options, Insider Trading, ATYR Pharma, Director Compensation, Beneficial Ownership, Securities Exchange Act